Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short-term Investments: 2014-2024

Historic Short-term Investments for Anika Therapeutics (ANIK) over the last 11 years, with Dec 2024 value amounting to $23.6 million.

  • Anika Therapeutics' Short-term Investments fell 21.76% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 21.76%. This contributed to the annual value of $23.6 million for FY2024, which is 10.49% down from last year.
  • As of FY2024, Anika Therapeutics' Short-term Investments stood at $23.6 million, which was down 10.49% from $26.4 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Short-term Investments registered a high of $34.6 million during FY2022, and its lowest value of $2.5 million during FY2020.
  • Moreover, its 3-year median value for Short-term Investments was $26.4 million (2023), whereas its average is $28.2 million.
  • As far as peak fluctuations go, Anika Therapeutics' Short-term Investments tumbled by 90.90% in 2020, and later skyrocketed by 1,093.24% in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' Short-term Investments stood at $2.5 million in 2020, then soared by 1,093.24% to $29.8 million in 2021, then climbed by 16.03% to $34.6 million in 2022, then declined by 23.87% to $26.4 million in 2023, then dropped by 10.49% to $23.6 million in 2024.